Skip to Main Content

It was just last month, with the Covid-19 situation having calmed down in Kyiv, that Ivan Kondratov had been able to return to his office a couple days per week. He managed a slew of medicinal chemistry projects, including the building of “target libraries” for clients, mostly large biopharma companies around the world.

His employer, Enamine, had become a pillar of global drug development, its Rolodex of clients steadily growing along with its catalog of chemical compounds for drugmakers to test in creating potential treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment